By switaschek, 1 September, 2020 If non HIV immunocompromise e g organ txp chronic steroids Reasonable to extrapolate recs for HIV pts per ACOG 6 individualize frequency based on health care team per ACS 7
By switaschek, 1 September, 2020 If HIV increased screening recommended w no upper age limit visually inspect genitalia anal canal at time of screenings for warts intraepithelial neoplasia invasive CA 1
By switaschek, 1 September, 2020 If s p hysterectomy w cervix removal for benign dz or gender affirmation vaginal CA screening not recommended 1 4
By switaschek, 1 September, 2020 If s p hysterectomy for CIN2 or worse dz vaginal cuff Pap annually per CDC NIH IDSA 1 ACOG6 recommends continued cytologic surveillance
By switaschek, 1 September, 2020 Screen w Pap alone or co tests Pap hrHPV after 3 NL annual Paps only or after 1 NL co test screen q3y1 2 annually if hx cervical CA per NCCN3 continue throughout lifetime no upper age limit 1
By switaschek, 1 September, 2020 If s p hysterectomy w cervix removal for benign dz or gender affirmation vaginal CA screening not recommended 1 3
By switaschek, 1 September, 2020 If s p hysterectomy for CIN2 or worse dz vaginal cuff Pap annually per CDC NIH IDSA 1 ACOG6 recommends continued cytologic surveillance
By switaschek, 1 September, 2020 Start Paps no later than 21 yo Invasive cervical cancer ICC incidence is exceedingly low among pts
By switaschek, 1 September, 2020 If non HIV immunocompromise e g organ txp chronic steroids Reasonable to extrapolate recs for HIV pts e g annual screening starting at 21 yo per ACOG 6 individualize frequency based on health care team per ACS 7
